Inspire Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Inspire Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-18	Closed	-$1K	–	395
2020 Q4	$1K	Buy	+18	New	+$715	﹤0.01%	739

Other funds holding IOVA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Inspire Advisors's IOVA Position: Q1 2021 in Review

Inspire Advisors sold out of Iovance Biotherapeutics (IOVA) in Q1 2021, closing a stake of 18 shares — an estimated $1K sold.

Inspire Advisors first reported a position in IOVA in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 252 funds tracked by Wall St. Rank hold IOVA as of Q1 2021.

Inspire Advisors reported no remaining Iovance Biotherapeutics position as of Q1 2021 after selling out during the quarter.
Inspire Advisors sold 18 Iovance Biotherapeutics shares in Q1 2021, an estimated $1K.
Inspire Advisors first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 1 quarter.
Inspire Advisors's Iovance Biotherapeutics position peaked at $1K in Q4 2020.
252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2021.

Based on Inspire Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.